Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
59
ASMB Quote, Financials, Valuation and Earnings
Last price:
$32.95
Seasonality move
:
12.32%
Day range:
$35.03 - $38.99
52-week range:
$7.75 - $39.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.55x
P/B ratio:
2.82x
Volume:
600K
Avg. volume:
149.7K
1-year change:
137.87%
Market cap:
$515.8M
Revenue:
$28.5M
EPS (TTM):
-$4.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ASMB
Assembly Biosciences, Inc.
|
$7.5M | -$0.65 | 0.89% | -46.09% | $47.75 |
|
ARVN
Arvinas, Inc.
|
$27.6M | -$0.74 | -37.06% | -11.21% | $12.44 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$180.2M | $0.82 | 12.33% | 60.84% | $61.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ASMB
Assembly Biosciences, Inc.
|
$32.61 | $47.75 | $515.8M | -- | $0.00 | 0% | 7.55x |
|
ARVN
Arvinas, Inc.
|
$12.17 | $12.44 | $781.3M | -- | $0.00 | 0% | 2.83x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.57 | $0.85 | $575.9M | 7.68x | $0.80 | 0% | 8.88x |
|
PFE
Pfizer Inc.
|
$24.88 | $28.62 | $141.5B | 14.50x | $0.43 | 6.91% | 2.26x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$51.71 | $61.33 | $3B | 41.17x | $0.00 | 0% | 4.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ASMB
Assembly Biosciences, Inc.
|
1.49% | 3.596 | 0.68% | 4.37x |
|
ARVN
Arvinas, Inc.
|
1.66% | 2.758 | 1.57% | 5.58x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
3.87% | 0.900 | 1.55% | 1.37x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ASMB
Assembly Biosciences, Inc.
|
$10.8M | -$10.9M | -64.14% | -67.09% | -100.87% | -$15.2M |
|
ARVN
Arvinas, Inc.
|
$40.6M | -$44M | -9.68% | -9.81% | -105.01% | -$59.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$148.3M | -$61M | -1.78% | -1.84% | -31.77% | -$61.8M |
Assembly Biosciences, Inc. vs. Competitors
-
Which has Higher Returns ASMB or ARVN?
Arvinas, Inc. has a net margin of -85.24% compared to Assembly Biosciences, Inc.'s net margin of -83.77%. Assembly Biosciences, Inc.'s return on equity of -67.09% beat Arvinas, Inc.'s return on equity of -9.81%.
Company Gross Margin Earnings Per Share Invested Capital ASMBAssembly Biosciences, Inc.99.7% -$0.72 $185.5M ARVNArvinas, Inc.96.9% -$0.48 $573.9M -
What do Analysts Say About ASMB or ARVN?
Assembly Biosciences, Inc. has a consensus price target of $47.75, signalling upside risk potential of 31.98%. On the other hand Arvinas, Inc. has an analysts' consensus of $12.44 which suggests that it could grow by 0.95%. Given that Assembly Biosciences, Inc. has higher upside potential than Arvinas, Inc., analysts believe Assembly Biosciences, Inc. is more attractive than Arvinas, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASMBAssembly Biosciences, Inc.4 0 0 ARVNArvinas, Inc.7 9 1 -
Is ASMB or ARVN More Risky?
Assembly Biosciences, Inc. has a beta of 1.138, which suggesting that the stock is 13.805% more volatile than S&P 500. In comparison Arvinas, Inc. has a beta of 2.446, suggesting its more volatile than the S&P 500 by 144.578%.
-
Which is a Better Dividend Stock ASMB or ARVN?
Assembly Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assembly Biosciences, Inc. pays -- of its earnings as a dividend. Arvinas, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASMB or ARVN?
Assembly Biosciences, Inc. quarterly revenues are $10.8M, which are smaller than Arvinas, Inc. quarterly revenues of $41.9M. Assembly Biosciences, Inc.'s net income of -$9.2M is higher than Arvinas, Inc.'s net income of -$35.1M. Notably, Assembly Biosciences, Inc.'s price-to-earnings ratio is -- while Arvinas, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences, Inc. is 7.55x versus 2.83x for Arvinas, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASMBAssembly Biosciences, Inc.7.55x -- $10.8M -$9.2M ARVNArvinas, Inc.2.83x -- $41.9M -$35.1M
-
Which has Higher Returns ASMB or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -85.24% compared to Assembly Biosciences, Inc.'s net margin of -255.85%. Assembly Biosciences, Inc.'s return on equity of -67.09% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ASMBAssembly Biosciences, Inc.99.7% -$0.72 $185.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ASMB or NBY?
Assembly Biosciences, Inc. has a consensus price target of $47.75, signalling upside risk potential of 31.98%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -81.4%. Given that Assembly Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Assembly Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASMBAssembly Biosciences, Inc.4 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ASMB or NBY More Risky?
Assembly Biosciences, Inc. has a beta of 1.138, which suggesting that the stock is 13.805% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ASMB or NBY?
Assembly Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Assembly Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASMB or NBY?
Assembly Biosciences, Inc. quarterly revenues are $10.8M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Assembly Biosciences, Inc.'s net income of -$9.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Assembly Biosciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences, Inc. is 7.55x versus 8.88x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASMBAssembly Biosciences, Inc.7.55x -- $10.8M -$9.2M NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M
-
Which has Higher Returns ASMB or PFE?
Pfizer Inc. has a net margin of -85.24% compared to Assembly Biosciences, Inc.'s net margin of 21.32%. Assembly Biosciences, Inc.'s return on equity of -67.09% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital ASMBAssembly Biosciences, Inc.99.7% -$0.72 $185.5M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About ASMB or PFE?
Assembly Biosciences, Inc. has a consensus price target of $47.75, signalling upside risk potential of 31.98%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 15.04%. Given that Assembly Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe Assembly Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASMBAssembly Biosciences, Inc.4 0 0 PFEPfizer Inc.7 15 1 -
Is ASMB or PFE More Risky?
Assembly Biosciences, Inc. has a beta of 1.138, which suggesting that the stock is 13.805% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock ASMB or PFE?
Assembly Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Assembly Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios ASMB or PFE?
Assembly Biosciences, Inc. quarterly revenues are $10.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Assembly Biosciences, Inc.'s net income of -$9.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Assembly Biosciences, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences, Inc. is 7.55x versus 2.26x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASMBAssembly Biosciences, Inc.7.55x -- $10.8M -$9.2M PFEPfizer Inc.2.26x 14.50x $16.7B $3.6B
-
Which has Higher Returns ASMB or PTN?
Palatin Technologies has a net margin of -85.24% compared to Assembly Biosciences, Inc.'s net margin of --. Assembly Biosciences, Inc.'s return on equity of -67.09% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ASMBAssembly Biosciences, Inc.99.7% -$0.72 $185.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ASMB or PTN?
Assembly Biosciences, Inc. has a consensus price target of $47.75, signalling upside risk potential of 31.98%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Assembly Biosciences, Inc., analysts believe Palatin Technologies is more attractive than Assembly Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASMBAssembly Biosciences, Inc.4 0 0 PTNPalatin Technologies0 0 0 -
Is ASMB or PTN More Risky?
Assembly Biosciences, Inc. has a beta of 1.138, which suggesting that the stock is 13.805% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ASMB or PTN?
Assembly Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assembly Biosciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASMB or PTN?
Assembly Biosciences, Inc. quarterly revenues are $10.8M, which are larger than Palatin Technologies quarterly revenues of --. Assembly Biosciences, Inc.'s net income of -$9.2M is higher than Palatin Technologies's net income of --. Notably, Assembly Biosciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences, Inc. is 7.55x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASMBAssembly Biosciences, Inc.7.55x -- $10.8M -$9.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ASMB or SUPN?
Supernus Pharmaceuticals, Inc. has a net margin of -85.24% compared to Assembly Biosciences, Inc.'s net margin of -23.49%. Assembly Biosciences, Inc.'s return on equity of -67.09% beat Supernus Pharmaceuticals, Inc.'s return on equity of -1.84%.
Company Gross Margin Earnings Per Share Invested Capital ASMBAssembly Biosciences, Inc.99.7% -$0.72 $185.5M SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B -
What do Analysts Say About ASMB or SUPN?
Assembly Biosciences, Inc. has a consensus price target of $47.75, signalling upside risk potential of 31.98%. On the other hand Supernus Pharmaceuticals, Inc. has an analysts' consensus of $61.33 which suggests that it could grow by 18.61%. Given that Assembly Biosciences, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Assembly Biosciences, Inc. is more attractive than Supernus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASMBAssembly Biosciences, Inc.4 0 0 SUPNSupernus Pharmaceuticals, Inc.4 1 0 -
Is ASMB or SUPN More Risky?
Assembly Biosciences, Inc. has a beta of 1.138, which suggesting that the stock is 13.805% more volatile than S&P 500. In comparison Supernus Pharmaceuticals, Inc. has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.462%.
-
Which is a Better Dividend Stock ASMB or SUPN?
Assembly Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assembly Biosciences, Inc. pays -- of its earnings as a dividend. Supernus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASMB or SUPN?
Assembly Biosciences, Inc. quarterly revenues are $10.8M, which are smaller than Supernus Pharmaceuticals, Inc. quarterly revenues of $192.1M. Assembly Biosciences, Inc.'s net income of -$9.2M is higher than Supernus Pharmaceuticals, Inc.'s net income of -$45.1M. Notably, Assembly Biosciences, Inc.'s price-to-earnings ratio is -- while Supernus Pharmaceuticals, Inc.'s PE ratio is 41.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences, Inc. is 7.55x versus 4.28x for Supernus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASMBAssembly Biosciences, Inc.7.55x -- $10.8M -$9.2M SUPNSupernus Pharmaceuticals, Inc.4.28x 41.17x $192.1M -$45.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
